TABLE 2

Clinical and biological parameters of 39 obese patients classified by the severity of liver fibroinflammatory scores

Hepatic fibroinflammatory score
P
Absent (0)Mild (1–2)Marked (>2)
n71715
F/M6/1 (86)16/1 (94)9/6 (60)
Age (years)41.4 ± 4.637.4 ± 2.539.0 ± 2.50.67
BMI (kg/m2)44.5 ± 3.547.6 ± 1.549.8 ± 1.90.28
Glucose (mmol/l)5.57 ± 0.395.79 ± 0.377.17 ± 0.71*0.11
Insulin (μU/ml)8.9 ± 1.7514.5 ± 1.7619.3 ± 2.820.036
QUICKI0.350.320.30*0.009
Type 2 diabetes03 (18)6 (40)0.09
Cholesterol (mmol/l)5.63 ± 0.245.23 ± 0.185.47 ± 0.290.56
HDL cholesterol (mmol/l)1.53 ± 0.151.35 ± 0.091.24 ± 0.060.26
Triglycerides (mmol/l)1.17 ± 0.101.26 ± 0.171.89 ± 0.29*0.11
Triglyceride–to–HDL cholesterol ratio0.84 ± 0.401.04 ± 0.251.74 ± 0.270.10
Leptin (ng/ml)49.8 ± 5.5269.4 ± 6.0056.7 ± 7.90.14
Adiponectin (μg/ml)7.19 ± 1.357.82 ± 0.905.59 ± 0.59*0.11
TNF-α (pg/ml)1.87 ± 0.161.85 ± 0.181.90 ± 0.110.84
Interleukin 6 (pg/ml)2.34 ± 0.612.54 ± 0.283.12 ± 0.410.33
High-sensitivity CRP (mg/dl)1.09 ± 0.410.79 ± 0.130.97 ± 0.220.82
Orosomucoid (g/l)1.00 ± 0.071.04 ± 0.050.93 ± 0.040.37
Serum amyloid A (μg/ml)21.8 ± 8.636.8 ± 15.539.4 ± 19.70.83
HDL <1.03 mmol/l (M), <1.29 mmol/l (F)2 (29)8 (44)8 (53)0.55
Hypertension ≥130/85 mmHg2 (29)6 (35)8 (53)0.44
Glucose ≥5.6 mmol/l3 (43)8 (44)10 (66)0.43
Triglycerides ≥1.7 mmol/l03 (18)8 (53)*0.015
Macrophages in omental WAT (%)22.2 ± 7.224.9 ± 3.840.7 ± 4.5*0.016
Adipocyte diameter omental WAT (μm)72.8 ± 7.672.3 ± 4.275.2 ± 3.10.75
Macrophages in subcutaneous WAT (%)15.5 ± 1.5314.9 ± 2.4712.2 ± 3.130.12
Adipocyte diameter in subcutaneous WAT (μm)95.8 ± 5.0584.0 ± 3.685.2 ± 2.80.11
AST (IU/l)19.7 ± 3.319.6 ± 1.230.4 ± 4.3*0.012
Alanine aminotransferase (IU/l)27.7 ± 10.925.9 ± 2.845.3 ± 9.30.043
γGT (mg/dl)32.3 ± 10.932.6 ± 3.945.4 ± 5.30.045
  • Data are the means ± SE, R2, or n (%). P values were obtained by ANOVA test for continuous values or by χ2 test for noncontinuous values. A different label (*, †, ‡) indicates significant differences using Student’s t test for each pair (P < 0.05 for

  • *

    * mild vs. marked,

  • absent vs. marked, and

  • absent vs. mild, respectively).